Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALTAFLUOR BENOX vs COLYTE-FLAVORED
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ALTAFLUOR BENOX is a combination of benoxinate, a local anesthetic that reversibly blocks sodium ion channels in nerve cell membranes, stabilizing the neuronal membrane and inhibiting the initiation and conduction of nerve impulses, and fluorescein, a fluorescent dye that stains epithelial defects in the cornea. Local anesthetic effect occurs within seconds.
Colyte is an osmotic laxative that induces diarrhea by retaining water in the colon through non-absorbable polyethylene glycol (PEG) and electrolytes, resulting in bowel cleansing.
FDA: For topical ophthalmic anesthesia and as a disclosing agent during ophthalmic procedures (e.g., tonometry, gonioscopy, removal of foreign bodies, sutures).,Off-label: No well-established off-label uses.
Colonoscopy preparation,Bowel cleansing prior to colorectal surgery,Bowel preparation for barium enema
1-2 drops of 0.4% benoxinate hydrochloride ophthalmic solution instilled into the conjunctival sac prior to diagnostic procedures or surgery.
4 liters orally as a single dose or in divided doses for colonoscopy preparation, or 1 liter orally every 10-15 minutes until 4 liters are consumed.
Terminal elimination half-life: 1.0–1.5 hours in adults with normal renal function; prolonged to 6–10 hours in severe renal impairment (Cr Cl <30 m L/min).
Not applicable; the drug acts locally in the gastrointestinal tract without significant systemic absorption. For the small fraction absorbed, a terminal elimination half-life of approximately 0.5-1 hour is estimated, but clinical relevance is negligible.
Systemic absorption is minimal after ophthalmic administration. Benoxinate is hydrolyzed by plasma esterases; metabolites are excreted renally. Fluorescein is metabolized via glucuronidation in the liver and excreted primarily in urine.
Polyethylene glycol (PEG) is not significantly metabolized; it is excreted unchanged in feces.
Renal: ~80% as unchanged drug; biliary/fecal: ~20% as metabolites (glucuronide conjugates).
Primarily eliminated in feces (≥95%) as intact drug via the gastrointestinal tract. Minimal systemic absorption; renal excretion accounts for <1% of the administered dose.
~40–45% bound to plasma proteins (primarily albumin).
Negligible (<5%) due to minimal systemic absorption; no specific binding proteins identified.
Vd: 1.2–1.8 L/kg (total body water distribution with moderate tissue binding; higher Vd may reflect extensive extravascular distribution).
Not meaningful due to negligible systemic absorption. The small fraction absorbed distributes primarily in extracellular fluid; a theoretical Vd would be low (<0.2 L/kg), but not clinically relevant.
Topical ophthalmic: minimal systemic absorption (<1% of dose enters systemic circulation).
Oral bioavailability is <1% due to minimal gastrointestinal absorption; the drug acts locally within the intestinal lumen.
No dose adjustment required; systemic absorption minimal.
Use with caution in patients with GFR <30 m L/min/1.73 m2; consider alternative bowel preparation. No specific dose adjustment defined.
No dose adjustment required; systemic absorption minimal.
No specific adjustment for Child-Pugh class A or B; use with caution in severe hepatic impairment (Child-Pugh C) due to risk of fluid and electrolyte disturbances.
Not recommended for pediatric use; safety and efficacy not established.
Not recommended for use in children; safety and efficacy not established.
No specific dose adjustment; use with caution due to possible increased sensitivity.
Use with caution; monitor for fluid and electrolyte imbalances, renal function, and volume status. Consider lower dose or split-dose regimen.
WARNING: CORNEAL TOXICITY AND IRREVERSIBLE CORNEAL DAMAGE. Prolonged use of topical anesthetics, including ALTAFLUOR BENOX, can result in delayed healing, corneal erosion, ulceration, perforation, and permanent vision loss. Use only for short-term procedures in a controlled clinical setting. Do not dispense to patients for self-administration.
There is no FDA black box warning for Colyte.
For topical ophthalmic use only. Not for injection.,Prolonged use may cause corneal toxicity; avoid repeated instillation.,Patients should avoid touching or rubbing the eye until anesthesia wears off.,Use with caution in patients with known hypersensitivity to ester-type anesthetics or fluorescein.,May cause transient stinging, burning, or conjunctival hyperemia.,Soft contact lenses should be removed before application and may be stained by fluorescein.
Risk of aspiration and esophageal perforation in patients with impaired gag reflex or altered consciousness,Electrolyte disturbances (e.g., hypernatremia, hypokalemia) in patients with renal impairment or dehydration,Cardiac arrhythmias in patients with electrolyte imbalances or QT prolongation,Colonic mucosal erosions or ulcerations with repeated use,Not for use in patients with gastrointestinal obstruction, perforation, or ileus
Known hypersensitivity to benoxinate, fluorescein, or any component of the formulation.,Prolonged use (not indicated for repeated or long-term treatment).,Use in patients with corneal abrasions or epithelial defects (may delay healing).
Gastrointestinal obstruction,Gastric retention,Bowel perforation,Toxic colitis,Toxic megacolon,History of severe electrolyte abnormalities,Known hypersensitivity to any component
No specific food interactions. Avoid alcohol as it may increase risk of dizziness or syncope during eye procedures.
Only clear liquids are allowed during bowel preparation. Avoid milk, cream, soups with solid ingredients, red or purple liquids, and alcohol. Solid food should be avoided at least 2 hours before starting the solution. No food interactions with the drug itself; dietary restrictions are for the procedure.
ALTAFLUOR BENOX contains fluorescein sodium and benoxinate hydrochloride. Fluorescein is not systemically absorbed in significant amounts after topical ophthalmic administration. No teratogenic effects are expected in any trimester. Benoxinate is an ester-type local anesthetic; systemic absorption is minimal. No known teratogenic risk.
Category C: Not associated with major malformations; limited data in pregnancy. No known teratogenicity; use only if clearly needed.
Minimal systemic absorption of fluorescein and benoxinate after topical ophthalmic use suggests negligible excretion into breast milk. M/P ratio is not applicable. Generally considered compatible with breastfeeding.
Excretion unknown; likely minimal systemic absorption. No M/P ratio available. Use with caution.
No dose adjustments needed. Pharmacokinetic changes in pregnancy do not affect topical ophthalmic drug delivery. Use standard adult dose, 1-2 drops prior to procedure.
No dosage adjustment required; monitor for hypovolemia due to increased plasma volume.
ALTAFLUOR BENOX (benzocaine 20% and fluorescein 0.25%) ophthalmic solution is used for corneal anesthesia and fluorescein staining. Apply 1-2 drops topically before procedures. Avoid prolonged use as benzocaine can cause corneal toxicity and delay healing. Fluorescein may stain soft contact lenses permanently; remove before use. Use with caution in patients with sulfonamide allergy (possible cross-reactivity with fluorescein). After use, patients should not rub eyes to prevent corneal abrasion.
Colyte-Flavored (PEG-3350 and electrolytes) is a colonic lavage solution used for bowel preparation prior to colonoscopy. Ensure adequate hydration: patients must consume all 4 liters (or split-dose regimen). Concurrent use of other laxatives or enemas is generally not needed. In patients with impaired gag reflex, renal insufficiency, or electrolyte abnormalities, use with caution. Monitor for bloating, nausea, and aspiration risk. Avoid use in GI obstruction, toxic colitis, or megacolon.
Do not touch the dropper tip to any surface to avoid contamination.,Remove contact lenses before use and wait at least 15 minutes before reinserting.,Temporary blurred vision and stinging may occur; avoid driving until vision clears.,Do not use more often or longer than prescribed to prevent eye damage.,Tell your doctor if you have sulfa allergy or if you are pregnant or breastfeeding.
Do not add any other ingredients to the solution.,Chill the solution before drinking to improve palatability.,Drink the entire volume over the prescribed period; do not eat solid foods until after the procedure.,Expect frequent, watery bowel movements; stay near a toilet.,Take other medications at least 1 hour before starting the solution, except as directed by your doctor.,Stop drinking the solution 2-3 hours before the procedure.,If severe bloating, abdominal pain, or vomiting occurs, pause and resume later.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALTAFLUOR BENOX vs COLYTE-FLAVORED, answered by our medical review team.
ALTAFLUOR BENOX is a Ophthalmic Diagnostic Agent with Anesthetic that works by ALTAFLUOR BENOX is a combination of benoxinate, a local anesthetic that reversibly blocks sodium ion channels in nerve cell membranes, stabilizing the neuronal membrane and inhibiting the initiation and conduction of nerve impulses, and fluorescein, a fluorescent dye that stains epithelial defects in the cornea. Local anesthetic effect occurs within seconds.. COLYTE-FLAVORED is a Osmotic Laxative that works by Colyte is an osmotic laxative that induces diarrhea by retaining water in the colon through non-absorbable polyethylene glycol (PEG) and electrolytes, resulting in bowel cleansing.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALTAFLUOR BENOX and COLYTE-FLAVORED depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALTAFLUOR BENOX is: 1-2 drops of 0.4% benoxinate hydrochloride ophthalmic solution instilled into the conjunctival sac prior to diagnostic procedures or surgery.. The standard adult dose of COLYTE-FLAVORED is: 4 liters orally as a single dose or in divided doses for colonoscopy preparation, or 1 liter orally every 10-15 minutes until 4 liters are consumed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALTAFLUOR BENOX and COLYTE-FLAVORED in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALTAFLUOR BENOX is classified as Category C. ALTAFLUOR BENOX contains fluorescein sodium and benoxinate hydrochloride. Fluorescein is not systemically absorbed in significant amounts after topical ophthalmic administration. N. COLYTE-FLAVORED is classified as Category C. Category C: Not associated with major malformations; limited data in pregnancy. No known teratogenicity; use only if clearly needed.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.